[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100605351":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":12,"centralContacts":17,"locations":23,"responsibleParty":171,"collaborators":10,"id":173,"slug":10,"hasResults":174,"nctId":175,"briefTitle":176,"officialTitle":177,"acronym":178,"eligibilityCriteria":179,"healthyVolunteers":174,"sex":180,"minAge":181,"maxAge":10,"enrollmentInfo":182,"targetDuration":10,"studyType":185,"phases":10,"briefSummary":186,"conditions":187,"keywords":189,"overallStatus":26,"whyStopped":10,"lastUpdateSubmitDate":191,"lastUpdatePostDateStruct":192,"startDateStruct":195,"completionDateStruct":197,"leadSponsor":199,"locationsCount":200},{"fullName":5,"class":6},"AstraZeneca","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":10},"LS-SCLC",null,"Patients with LS-SCLC who received platinum-based cCRT\u002FsCRT followed by durvalumab consolidation as first line treatment at the discretion of physicians.",[13],{"name":14,"affiliation":15,"role":16},"JinMing Yu, Doctor","Cancer Hospital of Shandong First Medical University (Shandong Cancer Institute, Shandong Cancer Hospital)","PRINCIPAL_INVESTIGATOR",[18],{"name":19,"role":20,"phone":21,"phoneExt":10,"email":22},"AstraZeneca Clinical Study Information Center","CONTACT","1-877-240-9479","information.center@astrazeneca.com",[24,35,42,49,56,63,70,78,82,89,96,103,110,117,124,131,138,143,150,157,164],{"facility":25,"status":26,"city":27,"state":10,"zip":10,"country":28,"cosmosGeoPoint":29,"geoPoint":34,"contacts":10},"Research Site","RECRUITING","Beijing","China",{"type":30,"coordinates":31},"Point",[32,33],116.39723,39.9075,{"lat":33,"lon":32},{"facility":25,"status":26,"city":36,"state":10,"zip":10,"country":28,"cosmosGeoPoint":37,"geoPoint":41,"contacts":10},"Cangzhou",{"type":30,"coordinates":38},[39,40],116.85334,38.31124,{"lat":40,"lon":39},{"facility":25,"status":26,"city":43,"state":10,"zip":10,"country":28,"cosmosGeoPoint":44,"geoPoint":48,"contacts":10},"Dongguan",{"type":30,"coordinates":45},[46,47],113.74866,23.01797,{"lat":47,"lon":46},{"facility":25,"status":26,"city":50,"state":10,"zip":10,"country":28,"cosmosGeoPoint":51,"geoPoint":55,"contacts":10},"Fuzhou",{"type":30,"coordinates":52},[53,54],119.30611,26.06139,{"lat":54,"lon":53},{"facility":25,"status":26,"city":57,"state":10,"zip":10,"country":28,"cosmosGeoPoint":58,"geoPoint":62,"contacts":10},"Guangzhou",{"type":30,"coordinates":59},[60,61],113.25,23.11667,{"lat":61,"lon":60},{"facility":25,"status":26,"city":64,"state":10,"zip":10,"country":28,"cosmosGeoPoint":65,"geoPoint":69,"contacts":10},"Huzhou",{"type":30,"coordinates":66},[67,68],120.0933,30.8703,{"lat":68,"lon":67},{"facility":25,"status":26,"city":71,"state":10,"zip":72,"country":28,"cosmosGeoPoint":73,"geoPoint":77,"contacts":10},"Jinan","250117",{"type":30,"coordinates":74},[75,76],116.99722,36.66833,{"lat":76,"lon":75},{"facility":25,"status":26,"city":71,"state":10,"zip":10,"country":28,"cosmosGeoPoint":79,"geoPoint":81,"contacts":10},{"type":30,"coordinates":80},[75,76],{"lat":76,"lon":75},{"facility":25,"status":26,"city":83,"state":10,"zip":10,"country":28,"cosmosGeoPoint":84,"geoPoint":88,"contacts":10},"Nanjing",{"type":30,"coordinates":85},[86,87],118.77778,32.06167,{"lat":87,"lon":86},{"facility":25,"status":26,"city":90,"state":10,"zip":10,"country":28,"cosmosGeoPoint":91,"geoPoint":95,"contacts":10},"Nanning",{"type":30,"coordinates":92},[93,94],108.31667,22.81667,{"lat":94,"lon":93},{"facility":25,"status":26,"city":97,"state":10,"zip":10,"country":28,"cosmosGeoPoint":98,"geoPoint":102,"contacts":10},"Ningbo",{"type":30,"coordinates":99},[100,101],121.54945,29.87819,{"lat":101,"lon":100},{"facility":25,"status":26,"city":104,"state":10,"zip":10,"country":28,"cosmosGeoPoint":105,"geoPoint":109,"contacts":10},"Shanghai",{"type":30,"coordinates":106},[107,108],121.45806,31.22222,{"lat":108,"lon":107},{"facility":25,"status":26,"city":111,"state":10,"zip":10,"country":28,"cosmosGeoPoint":112,"geoPoint":116,"contacts":10},"Shenyang",{"type":30,"coordinates":113},[114,115],123.43278,41.79222,{"lat":115,"lon":114},{"facility":25,"status":26,"city":118,"state":10,"zip":10,"country":28,"cosmosGeoPoint":119,"geoPoint":123,"contacts":10},"Shijiazhuang",{"type":30,"coordinates":120},[121,122],114.47861,38.04139,{"lat":122,"lon":121},{"facility":25,"status":26,"city":125,"state":10,"zip":10,"country":28,"cosmosGeoPoint":126,"geoPoint":130,"contacts":10},"Taiyuan",{"type":30,"coordinates":127},[128,129],112.56028,37.86944,{"lat":129,"lon":128},{"facility":25,"status":26,"city":132,"state":10,"zip":10,"country":28,"cosmosGeoPoint":133,"geoPoint":137,"contacts":10},"Tianjing",{"type":30,"coordinates":134},[135,136],120.77196,31.46583,{"lat":136,"lon":135},{"facility":25,"status":139,"city":132,"state":10,"zip":10,"country":28,"cosmosGeoPoint":140,"geoPoint":142,"contacts":10},"TERMINATED",{"type":30,"coordinates":141},[135,136],{"lat":136,"lon":135},{"facility":25,"status":26,"city":144,"state":10,"zip":10,"country":28,"cosmosGeoPoint":145,"geoPoint":149,"contacts":10},"Wuhan",{"type":30,"coordinates":146},[147,148],114.26667,30.58333,{"lat":148,"lon":147},{"facility":25,"status":26,"city":151,"state":10,"zip":10,"country":28,"cosmosGeoPoint":152,"geoPoint":156,"contacts":10},"Wuxi",{"type":30,"coordinates":153},[154,155],120.28857,31.56887,{"lat":155,"lon":154},{"facility":25,"status":26,"city":158,"state":10,"zip":10,"country":28,"cosmosGeoPoint":159,"geoPoint":163,"contacts":10},"Yangzhou",{"type":30,"coordinates":160},[161,162],119.43583,32.39722,{"lat":162,"lon":161},{"facility":25,"status":26,"city":165,"state":10,"zip":10,"country":28,"cosmosGeoPoint":166,"geoPoint":170,"contacts":10},"Zhengzhou",{"type":30,"coordinates":167},[168,169],113.64861,34.75778,{"lat":169,"lon":168},{"type":172,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100605351",false,"NCT07161388","Durvalumab Consolidation After Chemoradiation Therapy for Limited Stage SCLC in China","Durvalumab Consolidation After Chemoradiation Therapy (CRT) for Patients With Limited Stage Small-Cell Lung Cancer in China: A Multicentre, Observational Study (DREAM)","DREAM","Inclusion Criteria:\n\n* Able to provide informed consent\n* Age ≥18 years\n* Histologically or cytologically documented LS-SCLC (Stage I-III SCLC \\[T any, N any, M0\\] according to the American Joint Committee on Cancer Staging Manual \\[AJCC Cancer Staging Manual, 8th Edition\\], that can be safely treated with definitive radiation doses. Excludes T3-4 due to multiple lung nodules that are too extensive or have tumor\u002Fnodal volume that is too large to be encompassed in a tolerable radiation plan)\n* ECOG PS 0-2 (prior to the first dose of durvalumab after CRT)\n* No disease progression following cCRT\u002FsCRT (cCRT refers to chemotherapy and radiotherapy are administered with overlap; sCRT refers to chemotherapy and radiotherapy are delivered in a sequential manner with no overlap)\n* Patients who received platinum-based cCRT\u002FsCRT followed by durvalumab consolidation as first-line treatment at the discretion of physicians are eligible (the time interval from the end of cCRT\u002FsCRT to the first dose of durvalumab consolidation should be within 3 months)\n\n  * Patients who started durvalumab consolidation ≤3 months before enrolment in the study will be allowed (irrespective of whether they continue to receive durvalumab at time of enrolment or already discontinued treatment)\n\nExclusion Criteria:\n\n* Patients treated with CRT only without subsequent durvalumab consolidation\n* Patients received durvalumab or any other anti-PD-1\u002Fanti-PD-L1 antibodies along with CRT\n* Patients who previously were involved, or currently are, or plan to be involved in any other interventional anti-cancer clinical studies for LS-SCLC\n* Prior exposure to immune-mediated therapy including, but not limited to, other anti-PD-1, anti-PD-L1, and anti-PD-L2 antibodies, excluding therapeutic anticancer vaccines\n* Judgment by the investigator that the patient should not participate in the study because the patient is unlikely to comply with study procedures","ALL","18 Years",{"count":183,"type":184},200,"ESTIMATED","OBSERVATIONAL","This prospective, multicentre, observational study aims to assess the effectiveness and safety of durvalumab as consolidation treatment for patients with LS-SCLC who have not progressed following CRT in real-world setting.",[188],"Limited Stage Small-Cell Lung Cancer",[190],"SCLC","2026-06-23",{"date":193,"type":194},"2026-06-24","ACTUAL",{"date":196,"type":194},"2025-11-17",{"date":198,"type":184},"2028-09-30",{"name":5,"class":6},21]